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Tyrosine phosphorylationA distinct feature of hepatocellular carcinoma (HCC) is the tendency of tumor cells to disperse throughout the
liver. Nck family adaptor proteins function to couple tyrosine phosphorylation signals to regulate actin
cytoskeletal reorganization that leads to cell motility. In order to explore the role of Nck in HCC development,
we performed GST pull-down assay using the SH2 domain of Nck1 as bait. The resulting precipitates were
separated by 2-DE. Mass spectrometry analysis revealed a group of Nck1 SH2 domain-binding proteins that
were differentially expressed in HCC. One of these proteins, dermcidin (DCD), and its interaction with Nck1,
was further validated in vitro. GST pull-down assay revealed that Nck1 SH2 domain binds to the
phosphotyrosine residue at position 20 (Y20) of the DCD. Pervandate treatment signiﬁcantly enhanced the
interaction between DCD and Nck1. Moreover, we demonstrated that forced expression of DCD could activate
Rac1 and Cdc42 and promoted cell migration. Taken together, these data suggest a role of DCD in tumor
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Hepatocellular carcinoma (HCC) is one of the most common and
aggressive humanmalignancies [1]. Highmetastasis and recurrence rate
aremajor obstacles to further improve the long-termsurvival rate ofHCC
patients [2]. Accumulating evidence suggests that cell migration plays a
critical role in tumormetastasis and invasion. Cell migration is governed
by remodeling of the actin cytoskeleton, i.e., the dynamic assembly and
disassembly of ﬁlamentous actin. Malignant tumor cells often show
excessive cell protrusive activity due to aberrant activation of signaling
pathways that regulate actin cytoskeleton rearrangement [3,4].The Nck adaptor proteins consists three SH3 domains, followed by
a C-terminal SH2 domain. Both Caenorhabditis elegans and Drosophila
melanogaster have a single Nck gene, whereasmammals have two Nck
homologues, Nck1 and Nck2 (also named Grb4). The two murine Nck
gene products exhibit 68% amino acid identity to one another. Nck can
bind, via its SH2 domain, to a number of receptor tyrosine kinases
such as the platelet derived growth factor receptor (PDGFR), the
epidermal growth factor receptor (EGFR), and the ephrin receptor
(Eph), as well as tyrosine phosphorylated docking proteins such as
p62Dok-1 and p130Cas [5–7]. On the other hand, the Nck SH3
domains are capable of binding to proline-rich sequences on a host of
effecter proteins implicated in cytoskeleton regulation. For instance,
binding of Nck to Pak/PIX complex stimulates Rho GTPases Rac1 and
Cdc42 activation and regulates cell adhesion, migration as well as
gene transcription [8,9].
Accumulating evidence in both invertebrates and mammals
indicates that one of the major cellular functions of Nck is to link
phosphotyrosine signals to regulation of the actin cytoskeleton, which
is the prerequisite for various biological responses such as axon path
ﬁnding, migration, chemotaxis and endocytosis [10]. Because tumor
cells often possess aberrant kinase activation [11], it is possible that
the binding partners of the Nck SH2 domain in tumors are different
from those of normal tissues. In order to identify Nck SH2 domain
binding proteins associated with HCC development, we used the GST
fused Nck1 SH2 domain to pull down associated proteins from either
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the resulting complexes and differentially expressed protein spots
were analyzed by mass spectrometry. Our study identiﬁed dermcidin
(DCD), a protein that is upregulated in HCC, as a novel binding protein
of Nck1. We further demonstrated that DCD overexpression could
promote cell migration.
2. Materials and methods
2.1. HCC patient samples and cell lines
HCC tissues were collected from 21 HCC patients who underwent
hepatectomy at the First Afﬁliated Hospital of Sun-Yat Sen University.
None of these patients received preoperative chemotherapy or
radiotherapy. Normal liver tissues were obtained from 8 patients
diagnosed with liver hemangioma or cholelithiasis. Specimens were
obtained with written informed consent from all patients. The study
was carried out with prior approval of the Committees for Ethical
Review of Research involving Human Subjects of the First Afﬁliated
Hospital of Sun-Yat Sen University (Guangzhou, China).
The normal human liver cell line, Chang liver, the hepatoma cell
line HepG2, Hep3B, SMMC-7721 and BEL-7402, and an endothelial
cell line of hepatic origin SK-HEP-1 were obtained from the Cell Bank,
Chinese Academy of Medical Sciences (Shanghai, China). The cells
were maintained in high-glucose Dulbecco's modiﬁed Eagle's media
(DMEM) (Gibco, Australia) supplemented with 10% fetal bovine
serum (Gibco, Australia).
2.2. Plasmid constructs and transfection
The full-length dermcidin cDNA was ampliﬁed and cloned into the
pReciever M06 expression vector (FulenGen, Guangzhou, China). GST
tagged SH2 domain of Nck1 was generated by PCR ampliﬁcation of
human Nck1 template and ligated into pGEX-4T-3 expression vector.
The Y20F DCDmutant and the R308K Nck1mutant were generated by
site-directed mutagenesis kit according to the manufacturer's
instructions. The expression plasmids were transfected into cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer's instructions.
2.3. GST fusion protein puriﬁcation and GST pull-down assay
Escherichia coli (BL21) was transformed with pGEX-4T-3 or pGEX-
Nck1-SH2, and incubated with 0.2 mM isopropyl-β-D-1-thiogalacto-
pyranoside (IPTG) for 4 h. The GST fusion proteins were puriﬁed from
bacterial lysates with GSH-Sepharose 4B beads according to the
manufacturer's instruction (Amersham Biosciences, NJ, USA).
Tissue/Cell lysates were prepared and spun at 15,000×g for 15 min
and the supernatants were incubated with GST or GST-Nck1-SH2
conjugated Sepharose beads for 2 h at 4 °C. After extensive washing,
fusion proteins were eluted with glutathione elution buffer (10 mM
reduced glutathione in 50 mM Tris–HCl, pH 8.0) and desalted with 2-
DE cleaning up kit (Amersham Biosciences, NJ, USA).
2.4. 2-DE and image analysis
Protein samples (250 μg) were diluted to 450 μl with rehydration
solution (7 M urea, 4% CHAPS, 0.5% IPG ampholyte, 65 mM DTE, 2 M
thiourea, and 0.0002% bromophenol blue), and then loaded onto IPG
gel strips (pH 3–10 linear, 24 cm long, Amersham Biosciences, NJ,
USA). The ﬁrst dimensional separation, IEF, was carried out using the
IPGphor system (Amersham Biosciences, NJ, USA) at 18 °C with
8000 V for a total of 90 k VHS. After IEF, the IPG strips were subjected
to reduction with 2% DTE in equilibration solution (50 mM Tris–HCl,
pH 8.8, 6 M urea, 2% SDS, 30% glycerol), followed by alkylation with
2.5% iodoacetamide in the same buffer. Gels were stained with Silverstaining kit (Amersham Biosciences, NJ, USA) according to manufac-
turer's instruction. The developed gels were scanned as 2-DE images
using an Image scanner (Amersham Biosciences, NJ, USA), and then
analyzed using ImageMaster software (Amersham Biosciences, NJ,
USA).
2.5. In-gel digestion and protein identiﬁcation
2-DE gels of interest were washed in water/acetonitrile (ACN) 1:1
and then dehydrated in ACN. The gel pieces were air-dried and
rehydrated in 20 μl of 10 mM DTT, 0.1 M NH4HCO3. Reduction of
disulﬁde bonds was performed at 56 °C for 45 min. The supernatant
was discarded and cysteine residues were modiﬁed to S-carboxya-
midomethylcysteine in 55 mM iodoacetamide, 0.1 M NH4HCO3. After
washing with 0.1 M NH4HCO3/ACN (1:1) for 15 min followed by ACN,
the gel pieces were air-dried, rehydrated in chilled 50 mM NH4HCO3
and 12.5 ng/μl trypsin, and incubated at 37 °C overnight. The
supernatant was collected and peptides were extracted from the gel
twice with 50 mM NH4HCO3/ACN (1:1) followed by 5% formic acid/
ACN (1:1). The combined extracts were evaporated to dryness in a
vacuum centrifuge. Prior to mass spectrometric analysis, peptides
were re-dissolved in 10 μl of 0.1% formic acid. Online peptide
separation was performed after trapping each sample on
180 μm×20 mm Symmetry® C18 Nano Acquity™ UPLC™ column
with 1% ACN and 0.1% formic acid at 15 ml/min ﬂow rate following the
separation on a 75 μm×250 mm BEH130 column (Nano Aquity™
UPLC™) with a 50 min gradient from 5 to 95% ACN and 0.1% formic
acid at a ﬂow rate of 300 nl/min. A tapered fused silica was used as an
emitter. Mass analyses were performed with a Quadruple Time of
Flight mass spectrometer (Q Tof, Waters, USA). The mass spectrom-
eter was operated in a data-dependent mode to automatically switch
betweenMS andMS/MS acquisition. SurveyMS spectra (fromm/z 400
to 1800) were acquired in the Q Tof, and the four most intense ions in
each survey scan were fragmented and analyzed. Proteins were
identiﬁed by automated database searching (Spectrum Mill, Agilent
technologies and MASCOT, matrix-science) of all MS and MS/MS
spectra using the IPI Human, Swiss-Prot and NCBinr databases. Raw
data ﬁles were converted to .pkl ﬁles by the ProteinLynx Global Server
(PLGS), Waters Corp software utility. Search parameters were set as
follows: MS accuracy, 0.15 Da; MS/MS accuracy, 0.15 Da; two missed
cleavage allowed; variable carbamidomethyl modiﬁcation of cystine
and variable oxidation of methionine and all entries of the databases
were searched.
2.6. Western blot and immunoprecipitation
Western blot and immunoprecipitation were performed as
described previously [12]. Dermcidin antibody and HA tag antibody
were from Abcam (Cambridge, MA). Anti-Nck1 was from Santa Cruz
(CA, USA). GAPDH was from Sigma-Aldrich (St. Louis, MO, USA).
2.7. Rho family small GTPase activation assay
The intracellular activities of Rho family GTPases Rac1 and Cdc42
were examined using Rac1 and Cdc42 activation assay kits, respec-
tively (Upstate Biotechnology, Lake Placid, NY, USA) according to the
manufacturer's protocols. In brief, cells were rinsed with ice-cold PBS
and lysed with Mg2+ lysis/wash buffer. After clarifying the cell lysates
with glutathione agarose and quantifying the protein concentrations,
aliquots with equal amounts of proteins were incubated with Rac/
Cdc42 assay reagent (PAK-1 PBD, agarose) at 4 °C for 1 h, using the
GTPgS-pretreated lysates as positive controls. The precipitated GTP-
bound Rac1 and Cdc42 were then eluted in Laemmli reducing sample
buffer, resolved in a 12% SDS-PAGE, and immunoblotted with
monoclonal antibodies speciﬁc for Rac1 and Cdc42. Five percent of
the cell lysate were also resolved in a 10% SDS-PAGE and
Table 1
Clinical features of patients analyzed by 2DE.
Gender Age HBV AFP Diagnosis Edmonson
Normal 1 F 68 (−) (−) Hepatolithiasis
2 M 59 (−) (−) Hepatolithiasis
3 F 26 (−) (−) Hepatolithiasis
4 M 51 (−) (−) Hepatolithiasis
5 M 56 (−) (−) Hemangioma
6 F 40 (−) (−) Hepatolithiasis
7 F 54 (−) (−) Hepatolithiasis
8 F 55 (−) (−) Hepatolithiasis
HCC 1 M 41 HBsAg (+) HCC II
2 M 57 HBsAg (+) HCC II
3 M 40 HBsAg (+) HCC III
4 M 54 HBsAg (+) HCC II
5 M 79 HBeAb+HBcAb (+) HCC III
6 M 49 HBsAg (+) HCC II
7 M 55 HBsAg (+) HCC III
8 M 53 HBsAg (+) HCC II–III
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amount of Rac1 and Cdc42.
2.8. Migration assay
Migration assay was performed as described previously [13].
2.9. Statistic analysis
Statistical differences between two groups were determined by
the Student's t test. A Pb0.05 was considered statistically signiﬁcant.
The results were expressed as mean±SD from at least three
experiments.
3. Results
3.1. Proteomic analyses identiﬁed differentially expressed Nck1-SH2
binding proteins between HCC and normal liver tissue
The proteins extracted from HCC tissues and normal tissues
(Table 1) were pooled separately and incubated with puriﬁed GST-
Nck1-SH2. The protein complex binding to Nck1-SH2was eluted from
glutathione beads and separated by 2-DE. Representative gel images
of the protein complex binding to Nck1-SH2 in HCC and normal liver
tissue were shown in Fig. 1. A comparison of the 2-DE images revealed
that 28 protein spots were up-regulated in HCC more than twofold
compared to normal liver tissues (T/NN2), with 15 of them detected
only in HCC samples. Finally, 13 proteins were identiﬁed from 14
spots by mass spectrometry (Table 2), most of which have not
previously been reported to be associated with Nck1, nor with HCC.
Because DCD was previously reported as a candidate oncogene in
breast cancer [14], we selected it for further study.
3.2. Expression of DCD is signiﬁcantly increased in HCC tissues
Since the interaction between DCD and Nck-SH2 was only
detected in HCC tissues but not in normal liver tissues, we then
examined DCD expression in 21 HCC and adjacent non-cancerous
liver tissues byWestern blot. As shown in Fig. 2A–B, DCDwas detected
in all tumor tissues but not in the adjacent non-tumor tissues. We
further examined the expression of DCD in normal and HCC cells. As
shown in Fig. 2C, the protein level of DCD in a normal liver cell line
(Chang liver cell) is relatively lower than that in HCC cells such as
HepG2, Hep3B, SMMC-7721 and BEL-7402. It is interesting to note
that the level of DCD is extremely high in SK-HEP-1 cell which is a
high invasive endothelial cell line of hepatic origin (Fig. 2C),
suggesting that increased DCD expression might be associated with
tumor metastasis.
3.3. Interaction between DCD and Nck1 is tyrosine phosphorylation-
dependent
Since DCD was identiﬁed as a binding protein of the Nck1-SH2
domain in HCC tissues, we further conﬁrmed this interaction in vitro.
HA-tagged DCD was transiently transfected into SK-HEP-1 cells and
the interaction between DCD and Nck1-SH2 was examined by GST
pull-down assay. As shown in Fig. 3A, DCD bound to Nck1-SH2 but not
GST. Since DCD is highly expressed in SK-HEP-1 cells, we therefore
performed co-immunoprecipitation experiment to analyze the asso-
ciation of endogenous DCD with Nck1 in SK-HEP-1 cells. As shown in
Fig. 3B, DCD was detected by anti-DCD antibody in the anti-Nck1
immunoprecipitate, but not in the precipitate obtained using a control
IgG.
Since SH2 domains are known to bind to phosphotyrosine residues
in proteins, Nck1-DCD interaction should be in a phosphorylation-
dependent manner. To address this issue, we treated HA-tagged DCDtransfected cells with phosphatase inhibitor pervanadate. As shown in
Fig. 3C, the interaction between GST-Nck1 and DCD was enhanced by
pervanadate treatment. Analysis of DCD sequence revealed one
tyrosine residue, Tyr20, in DCD. Thus, site-directed mutagenesis was
employed to substitute Tyr20 to phenylalanine (Y20F). We next
transfected either wild type DCD or DCD mutant Y20F into SK-HEP-1
cells, respectively. Forty-eight hours after transfection, the interaction
between DCD and Nck1-SH2 was analyzed by GST pull down. As
shown in Fig. 3D, the interaction between Y20F and Nck1-SH2 was
dramatically attenuated compared to wild type DCD. Collectively,
these data indicate that the interaction between DCD and Nck1 is
tyrosine phosphorylation-dependent.
3.4. DCD expression activated Rho GTPases and promoted cell migration
via interaction with Nck1
It has been demonstrated that, upon receptor tyrosine kinases
activation, Nck binds to Pak/PIX complex and then leads to Rac1 and
Cdc42 activation. Therefore, to test the functionality of DCD–Nck1
interaction, SK-HEP-1 cells were transfected with wild type DCD or
Y20F mutant DCD, respectively. As shown in Fig. 4A and B,
overexpression of wild type DCD resulted in a remarkable increase
in the activation of both Rac1 and Cdc42 compared with control cells.
However, both Rac1 and Cdc42 activities in Y20F mutant transfected
cells were dramatically lower than that of wild type DCD transfected
cells.
Given the important role of Rac1 and Cdc42 activation on cell
migration, we next examined the effect of overexpressing DCD on cell
migration. Boyden chamber cell motility assay revealed that DCD-
transfected cells displayed a greater ability to migrate across the ﬁlter
than the vector controls (Fig. 4C). Quantiﬁcation of the data indicated
an almost 100-fold increase in the number of cells migrating across
the transwell ﬁlters for DCD-overexpressing cells over control cells
(Fig. 4D), whereas, the motility of Y20F mutant transfected cells
drastically reduced compared to wild type DCD.
It has been reported previously that Nck1-R308K mutant disrupts
the ability of the SH2 domain to bind to phosphotyrosine residues
[15]. To conﬁrm the role of Nck1-SH2 domain in DCD-mediated cell
migration, we cotransfected HA-tagged DCD with Nck1-WT or Nck1-
R308K into SK-HEP-1 cells. Forty-eight hours after transfection, the
immunoprecipitated proteins by Nck1 antibody were analyzed by
Western blot and signiﬁcant amount of DCD was found to be
coprecipitated with Nck1-WT but not with Nck1-R308K (Fig. 5A).
Moreover, Nck1-R308K dramatically inhibited DCD-augmented cell
migration (Fig. 5B–C) compared with wild type Nck1. Collectively,
these ﬁndings indicated that DCD overexpression, via interaction with
Nck1-SH2, activates Rho GTPases and promotes cell migration.
Fig. 1. Differentially expressed Nck-SH2 binding proteins in normal versus HCC samples. Representative 2-DE images of GST-Nck1-SH2 binding proteins isolated from normal liver
tissue (A) and HCC samples (B). The signiﬁcantly up-regulated spots (T/NN2) in HCC are marked with numbers. T, HCC sample; N, normal liver tissue.
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Using 2 DE combined with MS analysis, we successfully identiﬁed
DCD as a novel binding protein of SH2 domain of Nck1 in HCC tissues.
Western blot demonstrated the increased expression of DCD in HCC
samples compared with adjacent non-tumor tissues. Consistent with
our data, DCD has been previously shown as a candidate oncogene
overexpressed in 10% of invasive breast carcinomas [14]. In addition, a
small proteolytic peptide, proteolysis-inducing factor (PIF), derived
from the protein encoded by the dermcidin gene was identiﬁed as a
cachectic factor and was puriﬁed from a cachexia- inducing murine
tumor and in the urine of weight-losing patients with pancreatic
cancer [16,17].The oncogenic function of DCD seems to be versatile in different
tumors. It has been shown that DCD enhanced cell growth and
survival by reducing serum dependency in breast cancer cells [14]. In
hepatoma HuH7 cells, overexpression of DCD improved cell survival
under oxidative stress by decreasing necrosis and increasing the
number of cells undergoing apoptosis. The growth and survival-
promoting effects of DCD in HuH7 cells have been shown to involve
different pathways [18]. Moreover, it has been reported that the
induction of skeletal muscle proteolysis by PIF is mediated through
increasing NF-κB accumulation in the nucleus [19]. In the present
study, we provided evidence that the expression of DCD was
upregulated in hepatoma cells than that of normal liver cells. It is
noteworthy that the expression of DCD is particularly high in SK-HEP-
Table 2
Differentially expressed Nck-SH2 binding proteins in HCC tissues.
Spot
number
SwissProt
ID
Protein name MW
(KDa)
No. of
matched
peptide
T/N
ratio
T14 Q9NTJ3 Structural maintenance of
chromosomes protein 4
147.18 4 N2
T35 P16152 Carbonyl reductase [NADPH] 1 30.37 4 N2
T44 Q86YZ3 Hornerin 282.39 5 N2
T52 P60660 Myosin light polypeptide 6 16.93 1 N2
T54 Q969J3 Loss of heterozygosity 12
chromosomal region 1
22.22 3 N2
T56 P62736 Actin, aortic smooth muscle 42 2 N2
T25 Q99943 1-acyl-sn-glycerol-3-phosphate
acyltransferase alpha
31.71 1 nd N
T32 Q6T4R5 Nance-Horan syndrome protein 176.7 2 nd N
T33 Q86YZ3 Hornerin 282.39 12 nd N
T42 Q99583 Max-binding protein MNT 62.3 2 nd N
T57 P60709 Actin, cytoplasmic 1 41.74 10 nd N
T58 P81605 Dermcidin [Precursor] 11.28 2 nd N
T63 Q92556 Engulfment and cell motility
protein 1
83.83 1 nd N
T70 P60059 Protein transport protein Sec61
subunit gamma
7.74 4 nd N
nd N, not detected in normal tissue.
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suggesting a role of DCD in tumor metastasis. Therefore, we think
this cell line is suitable for analyzing the role of DCD in promoting cellFig. 2. (A) DCD is overexpressed in HCC tissues. Total protein extracted from tumor tissue (T
same membrane was re-blotted with an anti-GAPDH antibody to verify equal loading. (B) Q
tissues. The DCD signal was normalized to that of GAPDH for comparison. Data are express
tissue. (C) Expression of DCD in normal and tumor cell lines was detected byWestern blot. Eq
with antibody against DCD. The same membrane was re-blotted with an anti-GAPDH antibmigration and the underlying mechanism. Further analysis revealed
that overexpression of DCD could promote SK-HEP-1 cell migration
and the mechanism is by activating Rho GTPase Rac1 and Cdc42.
Taken together, these data supported a role of DCD in tumor
metastasis.
Previous studies showed that the function of DCD is mediated via
the action of the core peptide of PIF [18,20]. In the present study, we
demonstrated that Tyr20 of DCD is essential for its interaction with
Nck1 and mutation of Tyr20 to phenylalanine abolished its binding to
Nck1 and attenuated cell migration. Since the Tyr residue is located
within the core peptide of PIF, it is plausible to postulate that the core
peptide of PIF is essential for the function of DCD in tumor metastasis.
In the present study, we identiﬁed DCD as a novel binding protein
of SH2 domain of Nck1. The Nck SH2 domain belongs to the group I
family, containing an aromatic amino acid (phenylalanine) at the βD5
position. Based on studies using degenerated phosphopeptide
libraries, the SH2 domain of Nck1 prefers a YDXV consensus motif
in tyrosine- phosphorylated proteins [21]. We showed that Nck1
binds to the phosphorylated Y20 of DCD. Interestingly, YDPE is not a
perfect ﬁt to the consensus binding motif of Nck. Consistent with our
ﬁnding, the binding motif for Nck1 in the PDGF receptor is YVPM
[22,23]. These studies suggest that some ﬂexibility exists in the
interaction between the SH2 domain and the phosphotyrosine motif.
Therefore, it is necessary to identify in vivo binding partners for
certain SH2 domain in order to fully understand the speciﬁcity of the
domain.) or adjacent non-tumor tissue (N) was immunoblotted with antibody against DCD. The
uantiﬁcation of (A) to show the relative abundance of DCD in tumor versus peri-tumor
ed as mean±SE for 21 pairs of samples. *Pb0.05 compared with adjacent non-tumor
ual amount of whole cell lysates extracted from indicated cell lines was immunoblotted
ody to verify equal loading.
Fig. 3. DCD interacts with Nck1 in a tyrosine phosphorylation-dependent manner. (A) GST-Nck1-SH2 was incubated with cell lysates from SK-HEP-1 cells transfected with either
empty vector or HA-tagged DCD. The bound protein was detected by immunoblot with anti-HA antibody. 10% of the SK-HEP-1 cell lysates used in GST pull-down assay was loaded to
verify equal loading. (B) SK-HEP-1 cell lysates were immunoprecipitated with an anti-Nck1 antibody or IgG as control, followed by anti-DCD or anti-Nck1 immunoblot. (C) SK-HEP-1
cells were transfected with HA-tagged DCD. 48 h after transfection, cells were treated with 100 μM pervanadate for 10 min and then cell lysates were harvested. The corresponding
cell lysate was incubated with puriﬁed GST-Nck1-SH2. Bound protein was detected by immunoblot using anti-HA antibody. 10% of the cell lysates used in GST pull-down assay was
loaded to verify equivalent loading. (D) SK-HEP-1 cells were transfected with HA-tagged wild type DCD or Y20F mutant. 48 h after transfection, cell lysates were harvested and the
corresponding cell lysate was incubated with puriﬁed GST-Nck1-SH2. Bound protein was detected by Western blot using anti-HA antibody. 10% of the cell lysates used in GST pull-
down assay was loaded to verify equivalent loading.
Fig. 4. Overexpression of DCD activated Rac1 and Cdc42 and promoted cell migration. SK-HEP-1 cells were transfected with empty vector, HA-tagged wild type DCD or Y20F mutant,
respectively. 48 h after transfection, the amount of active GTP-bound Rac1 (A) and Cdc42 (B) was determined by antibodies speciﬁc for Rac1 and Cdc42. (C) For Boyden chamber
motility assay, cells were seeded onto the ﬁlter in the upper compartment of the chamber and incubated for 18 h. Cells and cell extensions that migrated through the pores of
transwell plates were counted and reported in (D). Photographs were taken using a Nikon microscope (phase contrast). Magniﬁcation, 200×. ##Pb0.01 vs. vector transfected cells;
#Pb0.05 vs. vector transfected cells; *Pb0.05 vs. Y20F mutant DCD transfected cells.
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Fig. 5. Intact SH2 domain of Nck1 is important for DCD–Nck1 interaction and DCD-
induced cell migration. (A) SK-HEP-1 cells were co-transfected HA-tagged DCD with
either Nck1-WT or Nck1-R308K, respectively. 48 h after transfection, cell lysates were
immunoprecipitated with antibody against Nck followed by immunoblot with antibody
against HA or Nck respectively. (B) Boyden chamber motility assay was performed
according to the method described in Fig. 4. Magniﬁcation, 200×. *Pb0.05 vs. Nck-WT
transfected cells.
709S.-L. Shen et al. / Biochimica et Biophysica Acta 1812 (2011) 703–710Protein tyrosine kinases and protein tyrosine phosphatases play
pivotal role in a variety of important signaling pathways in
multicellular organisms and aberrant kinase activities are often
associated with malignant transformation [24,25]. Thus, proﬁling
the global state tyrosine phoshporylation state, especially comparing
the tyrosine phoshporylation state between normal and tumor
tissues, will provide a useful means for novel molecular diagnostic
approaches. The SH2 domain is a small modular protein domain that
binds speciﬁcally to tyrosine-phosphorylated peptide ligands [26].
Therefore, characterizing the SH2 domain binding protein complex
can enrich low-abundance tyrosine phosphorylated proteins and
efﬁciently capture information relevant to the activation state of
signaling pathways in cells and tissues. Machita et al. developed a SH2
proﬁling method based on far-Western blotting by using GST-SH2
fusion proteins as probes and proposed that SH2 binding proﬁles may
be useful as a molecular diagnostic tool for classifying tumor cells and
predicting clinical outcomes [27]. By combining afﬁnity puriﬁcation of
Grb2-SH2 domain binding proteins with SILAC, Blagoev et al.
identiﬁed 28 proteins, including EGFR and Shc, that were selectively
enriched after EGF stimulation in cells, suggesting this strategy is
effective in identifying functional protein complexes [28]. However,
all the studies were performed in cells lines. In the present study, we
applied this strategy to investigate proteins associated with a disease
and identiﬁed DCD as a novel Nck1-SH2 domain binding protein that
differentially expressed in HCC tissues.
It is noteworthy that the advantage of afﬁnity puriﬁcation of SH2
domain binding proteins is not limited to enriching low-abundance
tyrosine phosphorylated proteins. We were able not only to identify
DCD as a novel tyrosine phosphorylated protein but also to identify
Tyr20 as the phosphorylation site for SH2-binding. Moreover, based on
the role of Nck1 on actin polymerization, we demonstrated that the
functional consequence of highly expressed DCD is to activate Rho
GTPases, suggesting that this strategy is effective in identifying novelSH2 domains associated phosphorylated proteins and the correlated
signaling pathways.
Acknowledgments
This work is supported by grant 30871033 and 81071892 from the
National Science Foundation of China, grant 8251008901000014 from
the Natural Science Foundation of Guangdong province.
References
[1] J. Bruix, M. Sherman, Management of hepatocellular carcinoma, Hepatology 42
(2005) 1208–1236.
[2] X.D. Zhou, Recurrence and metastasis of hepatocellular carcinoma: progress and
prospects, Hepatobiliary Pancreat. Dis. Int. 1 (2002) 35–41.
[3] A.J. Ridley, M.A. Schwartz, K. Burridge, R.A. Firtel, M.H. Ginsberg, G. Borisy, J.T.
Parsons, A.R. Horwitz, Cell migration: integrating signals from front to back,
Science 302 (2003) 1704–1709.
[4] H. Yamaguchi, J. Condeelis, Regulation of the actin cytoskeleton in cancer cell
migration and invasion, Biochim. Biophys. Acta 1773 (2007) 642–652.
[5] F. Bladt, E. Aippersbach, S. Gelkop, G.A. Strasser, P. Nash, A. Tafuri, F.B. Gertler, T.
Pawson, The murine Nck SH2/SH3 adaptors are important for the development of
mesoderm-derived embryonic structures and for regulating the cellular actin
network, Mol. Cell. Biol. 23 (2003) 4586–4597.
[6] Y. Miyamoto, J. Yamauchi, N. Mizuno, H. Itoh, The adaptor protein Nck1 mediates
endothelin A receptor-regulated cell migration through the Cdc42-dependent c-Jun
N-terminal kinase pathway, J. Biol. Chem. 279 (2004) 34336–34342.
[7] N. Jones, I.M. Blasutig, V. Eremina, J.M. Ruston, F. Bladt, H. Li, H. Huang, L. Larose, S.
S. Li, T. Takano, S.E. Quaggin, T. Pawson, Nck adaptor proteins link nephrin to the
actin cytoskeleton of kidney podocytes, Nature 440 (2006) 818–823.
[8] Z. Li, M. Hannigan, Z. Mo, B. Liu, W. Lu, Y. Wu, A.V. Smrcka, G. Wu, L. Li, M. Liu, C.K.
Huang, D. Wu, Directional sensing requires G beta gamma-mediated PAK1 and
PIX alpha-dependent activation of Cdc42, Cell 114 (2003) 215–227.
[9] Z.S. Zhao, E. Manser, L. Lim, Interaction between PAK and nck: a template for Nck
targets and role of PAK autophosphorylation, Mol. Cell. Biol. 20 (2000)
3906–3917.
[10] W. Li, J. Fan, D.T. Woodley, Nck/Dock: an adapter between cell surface receptors
and the actin cytoskeleton, Oncogene 20 (2001) 6403–6417.
[11] L. Gossage, T. Eisen, Targeting multiple kinase pathways: a change in paradigm,
Clin. Cancer Res. 16 (2010) 1973–1978.
[12] X. Wang, J. Nie, Q. Zhou, W. Liu, F. Zhu, W. Chen, H. Mao, N. Luo, X. Dong, X. Yu,
Downregulation of Par-3 expression and disruption of Par complex integrity by
TGF-beta during the process of epithelial to mesenchymal transition in rat
proximal epithelial cells, Biochim. Biophys. Acta 1782 (2008) 51–59.
[13] J. Nie, Q. Wu, W. Liu, F. Zhu, F. Qiu, Q. Zhou, J. Fan, X. Dong, X. Yu, Ectopic
expression of Ligand-of-Numb protein X promoted TGF-beta induced epithelial to
mesenchymal transition of proximal tubular epithelial cells, Biochim. Biophys.
Acta 1792 (2009) 122–131.
[14] D. Porter, S. Weremowicz, K. Chin, P. Seth, A. Keshaviah, J. Lahti-Domenici, Y.K.
Bae, C.L. Monitto, A. Merlos-Suarez, J. Chan, C.M. Hulette, A. Richardson, C.C.
Morton, J. Marks, M. Duyao, R. Hruban, E. Gabrielson, R. Gelman, K. Polyak, A
neural survival factor is a candidate oncogene in breast cancer, Proc. Natl Acad. Sci.
U.S.A. 100 (2003) 10931–10936.
[15] T. Hu, G. Shi, L. Larose, G.M. Rivera, B.J. Mayer, R. Zhou, Regulation of process
retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1,
Biochemistry 48 (2009) 6369–6378.
[16] C.L. Monitto, S.M. Dong, J. Jen, D. Sidransky, Characterization of a human
homologue of proteolysis-inducing factor and its role in cancer cachexia, Clin.
Cancer Res. 10 (2004) 5862–5869.
[17] P. Todorov, P. Cariuk, T. McDevitt, B. Coles, K. Fearon, M. Tisdale, Characterization
of a cancer cachectic factor, Nature 379 (1996) 739–742.
[18] A.G. Lowrie, S.J. Wigmore, D.J. Wright, I.D. Waddell, J.A. Ross, Dermcidin
expression in hepatic cells improves survival without N-glycosylation, but
requires asparagine residues, Br. J. Cancer 94 (2006) 1663–1671.
[19] T.M. Watchorn, I. Waddell, N. Dowidar, J.A. Ross, Proteolysis-inducing factor
regulates hepatic gene expression via the transcription factors NF-(kappa)B and
STAT3, FASEB J. 15 (2001) 562–564.
[20] J.P. Lee Motoyama, H. Kim-Motoyama, P. Kim, H. Nakagama, K. Miyagawa, K. Suzuki,
Identiﬁcation of dermcidin in human gestational tissue and characterization of its
proteolytic activity, Biochem. Biophys. Res. Commun. 357 (2007) 828–833.
[21] I.M. Blasutig, L.A. New, A. Thanabalasuriar, T.K. Dayarathna, M. Goudreault, S.E.
Quaggin, S.S. Li, S. Gruenheid, N. Jones, T. Pawson, Phosphorylated YDXV motifs
and Nck SH2/SH3 adaptors act cooperatively to induce actin reorganization, Mol.
Cell. Biol. 28 (2008) 2035–2046.
[22] R. Nishimura, W. Li, A. Kashishian, A. Mondino, M. Zhou, J. Cooper, J. Schlessinger,
Two signaling molecules share a phosphotyrosine-containing binding site in the
platelet-derived growth factor receptor, Mol. Cell. Biol. 13 (1993) 6889–6896.
[23] L. Buday, L. Wunderlich, P. Tamas, The Nck family of adapter proteins: regulators
of actin cytoskeleton, Cell. Signal. 14 (2002) 723–731.
[24] A. Ostman, C. Hellberg, F.D. Bohmer, Protein-tyrosine phosphatases and cancer,
Nat. Rev. Cancer 6 (2006) 307–320.
[25] M.A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell 141
(2010) 1117–1134.
710 S.-L. Shen et al. / Biochimica et Biophysica Acta 1812 (2011) 703–710[26] B.A. Liu, K. Jablonowski, M. Raina, M. Arce, T. Pawson, P.D. Nash, The human and
mouse complement of SH2 domain proteins-establishing the boundaries of
phosphotyrosine signaling, Mol. Cell 22 (2006) 851–868.
[27] K. Machida, C.M. Thompson, K. Dierck, K. Jablonowski, S. Karkkainen, B. Liu, H.
Zhang, P.D. Nash, D.K. Newman, P. Nollau, T. Pawson, G.H. Renkema, K. Saksela, M.R. Schiller, D.G. Shin, B.J. Mayer, High-throughput phosphotyrosine proﬁling using
SH2 domains, Mol. Cell 26 (2007) 899–915.
[28] B. Blagoev, I. Kratchmarova, S.E. Ong, M. Nielsen, L.J. Foster, M. Mann, A
proteomics strategy to elucidate functional protein-protein interactions applied
to EGF signaling, Nat. Biotechnol. 21 (2003) 315–318.
